Engineered Sulfotransferase for Stable Anticoagulant Polysaccharide Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing anticoagulant polysaccharides, such as heparin, in vitro face challenges due to the instability of PAPS, which is necessary for sulfotransferase reactions, making large-scale synthesis difficult, and existing sulfotransferases are limited in their ability to react with aryl sulfate compounds as sulfo group donors.
Innovation Solution
Engineering sulfotransferase enzymes to recognize and react with aryl sulfate compounds as sulfo group donors, allowing for the synthesis of sulfated polysaccharides, including heparin, without the need for PAPS, by catalyzing the transfer of sulfo groups to heparosan-based polysaccharides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PAPS is used as the sulfo group donor in sulfotransferase reactions, then the sulfation of polysaccharides can proceed, but the reaction becomes unstable and unsuitable for large-scale synthesis
Solution Approach 1:
The patent changes the chemical parameter of the sulfo group donor from PAPS (which has short half-life and decomposes) to aryl sulfate compounds (which are stable and do not decompose). This parameter change resolves the contradiction by providing a stable, scalable alternative that maintains sulfation activity without the instability of PAPS.
2Adaptability or versatility
If natural sulfotransferase enzymes are used, then they can catalyze sulfation reactions, but they are limited in their ability to react with aryl sulfate compounds
Solution Approach 1:
The patent applies local quality by making specific amino acid mutations at critical positions in the enzyme's active site (local region) while maintaining the overall enzyme structure and function. These localized changes enable the enzyme to accept aryl sulfate compounds as substrates while preserving its catalytic activity and stability.
Solution Approach 2:
The patent creates a dynamic enzyme system where the engineered sulfotransferase can adapt to work with aryl sulfate compounds. The enzyme's active site is engineered to dynamically accommodate different substrate types, providing versatility while maintaining reaction stability through the engineered architecture.
3Manufacturing precision
If multiple sulfotransferase enzymes are used to achieve complete sulfation, then the desired polysaccharide product can be formed, but the process complexity increases
Solution Approach 1:
The patent creates a universal engineered sulfotransferase enzyme that can perform multiple sulfation functions. By engineering the enzyme to accept aryl sulfate compounds and catalyze transfer to various positions on the polysaccharide, a single enzyme type can replace multiple specialized enzymes, reducing process complexity while maintaining manufacturing precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the production of sulfated polysaccharides with anticoagulant activity, providing a viable alternative for clinical use by overcoming the limitations of existing methods and ensuring stability in large-scale synthesis.
Implementation Method 1
Each sulfo group transfer is catalyzed by a sulfotransferase enzyme
Implementation Method 2
sulfated polysaccharides, including heparin, are synthesized by the catalytic transfer of sulfate functional groups, also called 'sulfo groups', from a sulfo group donor to a polysaccharide
Data Source
AI summary
The present invention includes methods for preparing anticoagulant polysaccharides using several non-naturally occurring, engineered sulfotransferase enzymes that are designed to react with aryl sulfate compounds instead of the natural substrate, PAPS, to facilitate sulfo group transfer to polysaccharide sulfo group acceptors. Suitable aryl sulfate compounds include, but are not limited to, p-nitrophenyl sulfate or 4-nitrocatechol sulfate. Anticoagulant polysaccharides produced by methods of the present invention comprise N—, 3—O—, 6-O-sulfated glucosamine residues and 2-O sulfated hexuronic acid residues, have comparable anticoagulant activity compared to commercially-available anticoagulant polysaccharides, and can be utilized to form truncated anticoagulant polysaccharides having a reduced molecular weight.